{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:29:22Z","timestamp":1791916162611,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011198","name":"State Key Laboratory of Drug Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013152","name":"Shanghai Institute of Materia Medica Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bmcl.2026.130747","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:28:45Z","timestamp":1785698925000},"page":"130747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design and synthesis of dual-target CDK9-EZH2 inhibitors using a pharmacophore fusion strategy"],"prefix":"10.1016","volume":"141","author":[{"given":"Yixue","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aihuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youhong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfen","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"31","key":"10.1016\/j.bmcl.2026.130747_bb0005","doi-asserted-by":"crossref","first-page":"28819","DOI":"10.1074\/jbc.M502712200","article-title":"Analysis of the large inactive P-TEFb complex indicates that it contains one 7SK molecule, a dimer of HEXIM1 or HEXIM2, and two P-TEFb molecules containing Cdk9 phosphorylated at threonine 186","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2026.130747_bb0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","article-title":"Inhibitors of cyclin-dependent kinases as cancer therapeutics","volume":"173","author":"Whittaker","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130747_bb0015","doi-asserted-by":"crossref","first-page":"T211","DOI":"10.1530\/ERC-16-0299","article-title":"Targeting CDK9: a promising therapeutic opportunity in prostate cancer","volume":"23","author":"Rahaman","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"19","key":"10.1016\/j.bmcl.2026.130747_bb0020","doi-asserted-by":"crossref","first-page":"8667","DOI":"10.1021\/acs.jmedchem.6b00150","article-title":"Cyclin dependent kinase 9 inhibitors for Cancer therapy","volume":"59","author":"Sonawane","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130747_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.07.038","article-title":"Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer","volume":"181","author":"Wang","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"22","key":"10.1016\/j.bmcl.2026.130747_bb0030","doi-asserted-by":"crossref","first-page":"13228","DOI":"10.1021\/acs.jmedchem.0c00744","article-title":"Recent developments in the biology and medicinal chemistry of CDK9 inhibitors: an update","volume":"63","author":"Wu","year":"2020","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2026.130747_bb0035","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2016-09-741983","article-title":"Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia\/lymphoma","volume":"130","author":"Narita","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130747_bb0040","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.bmc.2006.10.063","article-title":"Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues","volume":"15","author":"Ahn","year":"2007","journal-title":"Bioorg Med Chem"},{"issue":"18","key":"10.1016\/j.bmcl.2026.130747_bb0045","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2009.26.1347","article-title":"Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma","volume":"28","author":"Tong","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.bmcl.2026.130747_bb0050","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","article-title":"Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies","volume":"63","author":"Barlaam","year":"2020","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130747_bb0055","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic Cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bmcl.2026.130747_bb0060","doi-asserted-by":"crossref","unstructured":"Richters A, Doyle SK, Freeman DB, et al. Modulating androgen receptor-driven transcription in prostate cancer with selective CDK9 inhibitors. Cell Chem Biol 2021;28(2): 134\u2013147.e114. DOI:https:\/\/doi.org\/10.1016\/j.chembiol.2020.10.001.","DOI":"10.1016\/j.chembiol.2020.10.001"},{"issue":"21","key":"10.1016\/j.bmcl.2026.130747_bb0065","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cmdc.201700447","article-title":"Identification of Atuveciclib (BAY\u00a01143572), the first highly selective, clinical PTEFb\/CDK9 inhibitor for the treatment of Cancer","volume":"12","author":"L\u00fccking","year":"2017","journal-title":"ChemMedChem"},{"issue":"13_Supplement","key":"10.1016\/j.bmcl.2026.130747_bb0070","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1538-7445.AM2017-984","article-title":"Abstract 984: identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops","volume":"77","author":"Luecking","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2026.130747_bb0075","doi-asserted-by":"crossref","first-page":"997","DOI":"10.18632\/oncotarget.28543","article-title":"The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies","volume":"14","author":"Zhou","year":"2023","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130747_bb0080","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/cdd.2012.80","article-title":"Cyclin-dependent kinases 7 and 9 specifically regulate neutrophil transcription and their inhibition drives apoptosis to promote resolution of inflammation","volume":"19","author":"Leitch","year":"2012","journal-title":"Cell Death & Differentiation"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130747_bb0085","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/leu.2015.31","article-title":"Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia","volume":"29","author":"Flynn","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130747_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051113","article-title":"An orally bioavailable and highly efficacious inhibitor of CDK9\/FLT3 for the treatment of acute myeloid leukemia","volume":"14","author":"Anshabo","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bmcl.2026.130747_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117367","article-title":"Design, synthesis and biological evaluation of dual CDK9\/PARP inhibitors for the treatment of cancer","volume":"287","author":"Huang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130747_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108577","article-title":"Design, synthesis, and biological evaluation of N-(2-amino-phenyl)-5-((4-aryl- pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives as novel inhibitors of CDK9 and class I HDACs for cancer treatment","volume":"162","author":"Chen","year":"2025","journal-title":"Bioorg Chem"},{"issue":"21","key":"10.1016\/j.bmcl.2026.130747_bb0105","doi-asserted-by":"crossref","first-page":"12411","DOI":"10.1080\/07391102.2023.2167000","article-title":"The anticancer and EGFR-TK\/CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives: X-ray crystallography, in vitro, and in silico mechanistic investigations","volume":"41","author":"Musa","year":"2023","journal-title":"J Biomol Struct Dyn"},{"issue":"17","key":"10.1016\/j.bmcl.2026.130747_bb0110","doi-asserted-by":"crossref","first-page":"15220","DOI":"10.1021\/acs.jmedchem.4c00837","article-title":"Discovery of novel 2-Aminopyridine-based and 2-Aminopyrimidine-based derivatives as potent CDK\/HDAC dual inhibitors for the treatment of refractory solid tumors and hematological malignancies","volume":"67","author":"Saidahmatov","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130747_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117773","article-title":"Design and synthesis of CDK9\/EZH2 dual-target inhibitors to achieve synergistic antitumor effects","volume":"294","author":"Tian","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130747_bb0120","series-title":"Urea Compound Containing 2-Heteroaromatic Ring Substitution, Preparation Method Therefor and Use Thereof","author":"Hu","year":"2023"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130747_bb0125","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/leu.2015.10","article-title":"CDK9 inhibition by dinaciclib potently suppresses mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo","volume":"29","author":"Gregory","year":"2015","journal-title":"Leukemia"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:09:02Z","timestamp":1788444542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26002143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":25,"alternative-id":["S0960894X26002143"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130747","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of dual-target CDK9-EZH2 inhibitors using a pharmacophore fusion strategy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130747"}}